Nefazodone is an antidepressant used in the treatment of depression. Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb.
- Mechanism
- Curator reviewed
Within the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT2) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.
- Primary indication
- For the treatment of depression.Curator reviewed · 1 structured indication
- Formula / weight
- C25H32ClN5O2 · 470.007 g/mol (avg)
- First approval
- Canada, 1998 · United States, 1994
Resolves to
VRBKIVRKKCLPHA-UHFFFAOYSA-NSMILESCCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Nefazodone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account